First-in-class Specific Inhibitor of Skp2-Mediated p27 Degradation

Specific Inhibitor of Skp2-Mediated p27 Degradation

Specific Inhibitor of Skp2-Mediated p27 Degradation

Novel inhibitor of OLIG2 in glioblastoma

Novel inhibitor of cell-cycle progression, inducing G0/G1 phase arrest and apoptosis in human hepatic carcinoma cells

Novel FLT3 and Wnt/β-catenin signaling inhibitor, displaying potent activity in models of FLT3-driven AML

Novel multikinase inhibitor, potently inhibiting angiogenesis-related kinases including VEGFR1/2/3, and FGFR2, and the Src kinase

Potent anticancer agent, downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK

Biological Active Reagents

Millepachine analog, inhibiting tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin

Novel inhibitor of NF

Potent influenza A virus (IAV) entry inhibitor, targeting a conserved region of hemagglutinin

Potent inhibitor of Dengue viruses (DENV), displaying activities against all four serotypes of DENV, as well as to a related flavivirus, West Nile virus (WNV), and an alphavirus, Sindbis virus (SINV)

Novel dual-targeted inhibitor of sphingosine kinase and microtubule polymerization

Selective, brain penetrant 5-HT(1B/D) receptor agonist

Dopamine D1 receptor agonist

Inhibitor of Aβ self-aggregation

Novel inhibitor of HIV-1 infection by blocking viral DNA nuclear entry

Novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity

Novel potent EGFR degrader, being capable of penetrating the cell membrane, also degrading an exon-20 insertion mutant form of EGFR (ASV duplication)

Novel selective EGFR degrader

Novel BRAF-targeting PROTAC, inducing efficient and potent degradation of mutant BRAF but sparing BRAFWT, inhibiting cell growth in mutant-BRAF driven cancer cells

Novel selective MDMX antagonist

Novel Inhibitor of the Disordered Protein, p27(Kip1)

Novel inhibitor of MAGE-A11 with robust activity in TR-FRET for disrupting MAGE-A11:PCF11 interaction (IC50 0.40 μM)

Unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1), also inhibiting HIV-2

Novel inhibitor of MAGE-A11 with robust activity in TR-FRET for disrupting MAGE-A11:PCF11 interactionm being cell permeable and having improved activity in the TR-FRET assay (IC50 0.13 µM)

Novel inhibitor of lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α and interleukin (IL)-6 on microglia, exhibiting anti-inflammatory activity through ER-stress-mediated autophagy, significantly inducing the conversion ratio of LC3 II/I and

Fluoroquinolone antibiotic, acting as antibacterial, antineoplastic, anti-Infective agents, Inhibiting DNA-gyrase and topoisomerase

Potent broad spectrm fluoroquinolone antibiotic